["{\n\"step_by_step_thinking\": \"Based on the question description, we know that the boy has asthma with seasonal exacerbation. The experimental therapy aims to reduce the exaggerated response observed during his asthmatic attacks by attenuating the activity of a certain mediator involved in class switching of antibodies. This suggests that the mediator is involved in allergic responses. IL-4 is a key player in the class switching of antibodies and is also involved in allergic reactions, making it a plausible candidate for the targeted mediator.\",\n\"answer_choice\": \"D\"\n}"]